Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy

References

• Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality pattern in Europe: estimates for 40 countries and 25 major cancer in 2018. Eur J of Cancer. 2018;103:356–387. doi:10.1016/j.ejca.2018.07.005
   PubMed Web of Science ®Google Scholar
• AIOM-AIRTUM. I numeri del cancro in Italia. Disponibile all’indirizzo; 2019. Available from: https://www.aiom.it/wp-content/uploads/2019/09/2019_Numeri_Cancro-operatori-web.pdf. Accessed March 15, 2023.
   Google Scholar
• Aljohar BA, Kilani MA. Breast cancer in Europe: epidemiology, risk factors, policies and strategies. a literature review. Glob J Health Sci. 2018;10:1. doi:10.1038/35021093
   Google Scholar
• Tamura K. Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer. Jpn J Clin Oncol. 2019;49:993–998. doi:10.1093/jjco/hyz151
   PubMed Web of Science ®Google Scholar
• Finn RS, Aleshin A, Slamon DJ. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Res. 2016;18:17. doi:10.1186/s13058-015-0661-5
   PubMed Web of Science ®Google Scholar
• Turner NC, Huang Bartlett C, Cristofanilli M. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373(17):1672–1673. doi:10.1056/NEJMoa1505270
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465–2472. doi:10.1200/JCO.2018.78.9909
   PubMed Web of Science ®Google Scholar
• Sledge GW, Toi M, Neven P, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol. 2019;6(1):116–124.
   Web of Science ®Google Scholar
• Iorfida M, Mazza M, Munzone E. Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- metastatic breast cancers: current perspectives. Breast Cancer. 2020;12:45–56. doi:10.2147/BCTT.S196240
   PubMed Web of Science ®Google Scholar
• Rugo HS, Haltner A, Zhan L, et al. Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer. J Comp Eff Res. 2021;10(6):457–467. PMID: 33626934. doi:10.2217/cer-2020-0272
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS)—explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16(2):231–250. doi:10.1016/j.jval.2013.02.002
   PubMed Web of Science ®Google Scholar
• Lloyd A, Nafees B, Narewska J, Dewilde S, Watkins J. Health state utilities for metastatic breast cancer. BrJCancer. 2006;95(6):683–690.
   Web of Science ®Google Scholar
• Fiorentino F, Urbinati D. First Italian guidelines for the economic evaluation of health technologies: how do they compare to NICE standards?. GIHTAD. 2021; 14:5. Available from: https://springerhealthcare.it/GIHTAD/wp-content/uploads/2021/07/GIHTAD_Fiorentino_14_5.pdf. Accessed March 15, 2023.
   Google Scholar
• Zhang T, Feng F, Zhao W, et al. Comparative efficacy of different targeted therapies plus fulvestrant for advanced breast cancer following progression on prior endocrine therapy: a network meta-analysis. Cancer Manag Res. 2018;10:5869–5880. PMID: 30510455. doi:10.2147/CMAR.S176172
   PubMed Web of Science ®Google Scholar
• Eli Lilly Italia S.P.A. SISTEMA DINAMICO DI ACQUISIZIONE FORNITURA DI FARMACI ED EMODERIVATI XXII APPALTO SPECIFICO. Rep.140/20. Available from: https://www.soresa.it/societatrasparente/Bandi%20di%20gara%20e%20contratti/Contratti/Farmaci%20ed%20Emoderivati/FARMACI/2020/XXII%20APPALTO%20SPECIFICO/rep.%20140_20%20-%20ELI%20LILLY%20ITALIA%20Spa.pdf. Accessed March 15, 2023.
   Google Scholar
• Soresa. Available from: https://www.soresa.it/pa/Pagine/Anagrafe/Farmaci-Emoderivati.aspx?Folder=Anagrafiche%20e%20Schede%20Prodotti/Farmaci%20ed%20Emoderivati/2021. Accessed March 15, 2023.
   Google Scholar
• Ministero della Salute. (Italian Ministry of Health). Tariffe delle prestazioni di assistenza specialistica ambulatoriale. [inpatient tariffs]. Gazzetta Ufficiale della Repubblica Italiana. Serie N.23; Supplemento N.8 del 28 gennaio; 2013.
   Google Scholar
• Ministero della Salute. (Italian Ministry of Health). Tariffe delle prestazioni di assistenza ospedaliera per acuti [DRG tariffs]. Gazzetta Ufficiale della Repubblica Italiana; Serie N.23; Supplemento N.8 del 28 gennaio; 2013.
   Google Scholar
• FARMADATI Italia software Tunnel®. Available from: https://www.farmadati.it/. Accessed March 15, 2023.
   Google Scholar
• Supplemento ordinario n 38/l alla Gazzetta Ufficiale Serie Generale n 201 del 29/8/2016. Available from: https://www.gazzettaufficiale.it/do/atto/serie_generale/caricaPdf?cdimg=16G0017700100010110001&dgu=2016-08-29&art.dataPubblicazioneGazzetta=2016-08-29&art.codiceRedazionale=16G00177&art.num=1&art.tiposerie=SG. Accessed March 15, 2023.
   Google Scholar
• Tariffe Lazio SAN_DCA_U00411_13_09_2017. Available from: https://www.ausl.latina.it/attachments/article/249/SAN_DCA_U00411_13_09_2017.pdf. Accessed March 15, 2023.
   Google Scholar
• Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices— budget impact analysis. Value Health. 2007;10(5):336–347. doi:10.1111/j.1524-4733.2007.00187.x
   PubMed Web of Science ®Google Scholar
• IQVIA. Il mercato Breast HER2- HR+, Studio multiclient, ottobre; 2021.
   Google Scholar
• Nuzzolese I, Montemurro F. Attrition in metastatic breast cancer: a metric to be reported in randomised clinical trials? Lancet Oncol. 2020;21(1):21–24. PMID: 31908294. doi:10.1016/S1470-2045(19)30792-2
   PubMed Web of Science ®Google Scholar
• Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the Economic Evaluation of Health Care Programmes. 4th. Oxford University Press;2015.
   Google Scholar
• Cleemput I, Neyt M, Thiry N, De Laet C, Leys M. Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions. Int J Technol Assess Health Care. 2011;27(1):71–76. doi:10.1017/S0266462310001194
   PubMed Web of Science ®Google Scholar
• Fattore G; Italian Health Economics Association Associazione Italiana di Economia Sanitaria – AIES. Proposta di linee guida per la valutazione economica degli interventi sanitari in Italia. [Italian guidelines proposal on how to conduct economic evaluation studies of health programs]. Pharmacoecon Ital Res Articles. 2009;11:83–93. Italian. doi:10.1007/BF03320660
   Google Scholar
• Lucioni C, Ravasio R. Come valutare i risultati di uno studio farmacoeconomico? PharmacoEcon Ital Res Articles. 2004;3:121–130. doi:10.1007/BF03320630;
   Google Scholar
• Messori A, Santarlasci B, Trippoli S, Vaiani M. Controvalore economico del farmaco e beneficio clinico: statodell’arte della metodologia e applicazione di un algoritmo farmacoeconomico. Pharmacoecon Ital Res Articles. 2003;5:53–67. doi:10.1007/BF03320605
   Google Scholar
• Cost Minimisation Analysis. York; York health economics consortium; 2016. Available from: https://yhec.co.uk/glossary/cost-minimisation-analysis/. Accessed March 15, 2023.
   Google Scholar
• Paravastu SC, Michaels JA. Michaels, in Core Topics in General and Emergency Surgery. Elsevier; 2014.
   Google Scholar
• Wang Y, Rui M, Guan X, Cao Y, Chen P. Cost-effectiveness analysis of abemaciclib plus fulvestrant in the second-line treatment of women with HR+/HER2- Advanced or metastatic breast cancer: a US payer perspective. Front Med. 2021;8:658747. PMID: 34150798. doi:10.3389/fmed.2021.658747
   Web of Science ®Google Scholar
• Avxentyev NA, Lubennikova EV, Frolov M. Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer. FARMAKOEKONOMIKA Mod Pharmacoeconomics Pharmacoepidemiol. 2019;12(4):279–290. doi:10.17749/2070-4909.2019.12.4.279-290)
   Google Scholar
• Rugo HS, Diéras V, Gelmon KA, et al. Impact of palbociclib plus letrozole on patient-reported health-related QoL: results from the PALOMA-2 trial. Ann Oncol. 2018;29(4):888–894. PMID: 29360932. doi:10.1093/annonc/mdy012
   PubMed Web of Science ®Google Scholar
• Garrison LP, Neumann PJ, Erickson P, et al. Using real-world data for coverage and payment decisions: the ISPOR real-world data task force report. Value Health. 2007;10:326–335. doi:10.1111/j.1524-4733.2007.00186
   PubMed Web of Science ®Google Scholar
• Ruggeri I, Bragato D, Colombo GL, Valla E, Di Matteo S. Cost and appropriateness of treating asthma with fixed-combination drugs in local health care units in Italy. Clinicoecon Outcomes Res. 2012;4:375–382. doi:10.2147/CEOR.S36499
   PubMedGoogle Scholar